Suraksha Diagnostic Ltd. · NSE:SURAKSHA
Suraksha Diagnostic — Q1 FY26 Earnings Presentation
31 slides from Suraksha Diagnostic's earnings presentation, Aug 9, 2025
Slide 1: Regulation 30 disclosure covering letter to stock exchanges
Date: 09 August 2025 To The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra -Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai- 400 051 Scrip Code: 544293 Scrip Symbol : SURAKSHA D
Slide 2: Suraksha Diagnostic Limited Investor Presentation Q1 FY26
SURAKSHA DIAGNOSTIC LIMITED Investor Presentation | Q1 FY26
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
Slide 4: Q1 FY26 Highlights
Suraksha Clinic & Diagnostics Q1 FY26 Highlights
Slide 5: Q1 FY26 At A Glance
Q1 FY26 At A Glance as of 30 June 2025 9 0.34 million 1.92 million ₹ 2,101 Labs Patients Served Tests Performed Revenue per patient (Q1 FY26) (Q1 FY26) (Q1 FY26) 58 314 26 ₹ 707 Diagnostic Centres Doctors EBITDA per patient CT Machines (Q1 FY26) 170 7 15 ₹ 38 million NABL accredited Revenue per lab
Slide 6: Consolidated Financial Performance – Q1 FY26
Consolidated Financial Performance – Q1 FY26 Total Income (₹ million) EBITDA (₹ million) PAT (₹ million) 35.8% 30.7% 34.0% 12.6% 11.0% 12.6% +19% +14% +20% 735 247 92 659 217 618 77 200 72 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Suraksha Diagnostic Limited| Investor P
Slide 7: Key Performance Metrics For Q1 FY26
Key Performance Metrics For Q1 FY26 Number of Centres Number of Tests (million) 58 1.92 47 1.52 Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 Revenue / Patient (₹) EBITDA / Patient(₹) 2121 752 2101 707 Q1 FY25 Q1 FY26 Q1 FY25 Q1 FY26 Suraksha Diagnostic Limited| Investor Presentation 6
Slide 8: Profit & Loss Statement (Consolidated)
Profit & Loss Statement (Consolidated) Particulars (₹ million) Q1 FY26 Q1 FY25 Y-o-Y Q4 FY25 Q-o-Q Revenue from Operations 725.86 607.32 650.95 Other Income 9.06 11.17 8.17 Total Revenue 734.92 618.48 18.83% 659.12 11.50% Cost of Material Consumed 87.51 66.37 88.48 Employee Benefit Expenses 127.75 1
Slide 9: Expanding Offerings Through Strategic Acquisition
Expanding Offerings Through Strategic Acquisition ABOUT FETOMAT • Incorporated in May 2021, Fetomat Wellness Private Limited (“Fetomat”) is a network of fertility and pregnancy care clinics • Fetomat focuses on pregnancy care, women’s ultrasound scans, prenatal diagnostics, genetic counselling and m
Slide 10: Genomics Could Be The Next Growth Lever
Genomics Could Be The Next Growth Lever ABOUT GENOMICS VERTICAL Global Genetic Testing Market Size ($ Bn) • In July 2025, we announced the launch of Suraksha Genomics, a new vertical for advanced genetic and molecular testing services 186.64 • Suraksha Genomics offers robust infrastructure and criti
Slide 11: Company Overview
Suraksha Clinic & Diagnostics Company Overview
Slide 12: Evolution To The Largest Integrated Diagnostic Chain In East India
Evolution To The Largest Integrated Diagnostic Chain In East India Received second round of funding from OrbiMed Exit of Lighthouse 53 centres Built fully Funds comprehensive 9 Labs diagnostic centre, 25 centres under brand IPO and listing on ‘Suraksha’ 5 centres BSE and NSE 4 Labs 1992 2007 2010 20
Slide 13: Deeply Entrenched In The Vital Geography Of West Bengal
Deeply Entrenched In The Vital Geography Of West Bengal 2 2 55 Centers in West Bengal No. of centres >10 centres 1 3 centres 2 centres 1 centres Bihar Assam • 4th most populous state in India • Fragmented market with low penetration of Population Legend Meghalaya West Bengal 1 chained diagnostic cen
Slide 14: Hub & Spoke Operating Model
Hub & Spoke Operating Model Modalities Offered Key Stats # of doctors & Area Hub Centres employees / centre Large MRI CT Scan USG Gastroenterology Neurology Pathology Centres 30-40 5,000 – 8,000 sq. ft X-Ray Cardiology Mammo OPG Dexa Medium 20-25 2,500 – 5,000 sq. ft Centres CT-Scan USG X-Ray Neurol
Slide 15: …..With Demonstrated Success
…..With Demonstrated Success Demonstrated success in Kolkata region with significant potential Operational Network(1) for future growth2 1 Central Lab (equipped to conduct all pathology 8 Satellite Labs 18 Hub Centres sample collection, basic and advanced radiology tests) (co-located with hub centre
Slide 16: Well-established Operational Network - Greater Economies Of Scale
Well-established Operational Network - Greater Economies Of Scale Report Flow Patient P.A.C.S RAD IMAGE (Software) (Scrutiny) (Report) Image/Report Flow Image Flow Patients Flow #18 #1 Hub Centre Flagship Reference Lab Doctor #8 #42 Spoke Centre SATELLITE LAB Polyclinic Doctor Customers Samples Coll
Slide 17: Well Equipped Clinical Infrastructure
Well Equipped Clinical Infrastructure Suraksha Diagnostic Limited| Investor Presentation 16
Slide 18: Customer Convenience Through Value Added Services
Customer Convenience Through Value Added Services Value Added Services enhancing customer experience and convenience Home Collection Allows samples to be collected from the consumers’ locations, such as their homes or offices SMS Alerts Customers receive an SMS to Customer download the report throug
Slide 19: Positioned To Leverage IT Infrastructure
Positioned To Leverage IT Infrastructure LIMS integration Our Laboratory Information Management System (LIMS) streamlines sample processing and report delivery. It ensures accuracy through barcoded labels and bi-directional analyser integration RIS and PACS workflow The Radiology Information System
Slide 20: Key Differentiating Factors
Key Differentiating Factors Polyclinic Diversified in terms of revenue from services 4% Revenue 49% 47% 132 1,000+ Chambers1 Doctors1 Pathology Radiology OPDConsultation Revenue contribution from Pathology, Radiology and OPD Omnichannel medical consultation services via online and offline modes thro
Slide 21: Experienced Board Of Directors
Experienced Board Of Directors Dr. Somnath Chatterjee Ritu Mittal Mr. Satish Kumar Verma Chairman & Joint Managing Director Joint Managing Director & Chief Non-Executive, Non-Independent Director Executive Officer ▪ Associated with Suraksha since ▪ 40+ years of experience in management ▪ Associated
Slide 22: Dynamic And Diverse Management Team To Deliver Next Phase Of Growth
Dynamic And Diverse Management Team To Deliver Next Phase Of Growth Ravindra K S Mamta Jain Niren Kaul Group Chief Financial Officer Company Secretary & Compliance Officer Chief Sales Officer ▪ Professional with over 20 years of extensive experience in ▪ 22+ years of experience, including with Bhart
Slide 23: Strategy And Outlook
Suraksha Clinic & Diagnostics Strategy And Outlook
Slide 24: Leveraging Strengths To Drive Competitive Advantage
Leveraging Strengths To Drive Competitive Advantage Largest diagnostic chain with a Technologically advanced Track record of profitability dominant position in Eastern clinical infrastructure and and consistent financial India; well-positioned to benefit trained personnel ensuring performance from t
Slide 25: Strategic Levers To Drive Future Growth
Strategic Levers To Drive Future Growth Expand footprint in Eastern and Enhance one-stop diagnostic North-Eastern India through model by augmenting medical organic as well as inorganic consultation services’ share route Strengthen B2B and Invest in technology to institutional partnerships to enhance
Slide 26: Targeting Organic And Inorganic Opportunities In Core And Adjacent Markets
Targeting Organic And Inorganic Opportunities In Core And Adjacent Markets Expand in adjacent geographies of Eastern and Consolidate leading position in the core geography Supplement organic growth with selective acquisitions North-Eastern India Open additional diagnostic centres and increase Identi
Slide 27: Industry Overview
Clinic & Diagnostics Industry Overview
Slide 28: Industry: Poised For High Growth; Shifting Towards Organized Market
Industry: Poised For High Growth; Shifting Towards Organized Market Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28 Organized players gaining market share from standalone labs at a steady rate CAGR 10-12% 1,275-1,375 36-40% 36-40% 860-870 13- 20- 17% 24% 45-49% 35-39% FY24E FY2
Slide 29: Eastern India - An “Underserved” Market With Premium Pricing
Eastern India - An “Underserved” Market With Premium Pricing Disparity in access to accredited testing services in Region has the lowest number of NABH East India(1) market also offers premium Eastern(1) India relative to population needs accredited hospitals pricing for diagnostic tests 430 80-90 8
Slide 30: Key Awards & Recognition
Key Awards & Recognition 2017 2019 2021 Best quality in service Best customer service in Business leader of the delivery(1) healthcare(1) year(2) 2021 2022 2023 Awards & certificate of Outstanding diagnostic Certificate of excellence excellence(3) chain of eastern India(4) in exemplary trust & commi
Slide 31: Thank You
Company : Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 investors@surakshanet.com Email: investors@surakshanet.com Investor Relations Advisors : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services Mr. Ashish Tendulkar ashish.tendu